Crestor Related Published Studies
Well-designed clinical trials related to Crestor (Rosuvastatin)
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. [2008.08.19]
Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. [2008.08]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008.04.21]
The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. [2008.04]
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. [2008.04]
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. [2008.03]
The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. [2008.03]
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. [2008.03]
Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. [2008.03]
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. [2008.02.01]
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. [2008.02]
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. [2008.02]
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. [2008.01.14]
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. [2008]
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). [2007.12]
Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. [2007.12]
Rosuvastatin in older patients with systolic heart failure. [2007.11.29]
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. [2007.11.01]
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). [2007.10.15]
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. [2007.10]
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. [2007.10]
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. [2007.08.18]
Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. [2007.07]
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). [2007.06.01]
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. [2007.06]
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. [2007.05]
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)] [2007.04]
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. [2007.03.28]
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. [2007.03.01]
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). [2007.03.01]
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. [2007.02.11]
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. [2006.10]
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). [2006.09.15]
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. [2006.06.01]
Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. [2006.06]
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). [2006.06]
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. [2006.05]
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. [2006.04]
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. [2006.03]
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention? [2006.01.16]
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in african-american patients in a six-week trial. [2006.01.15]
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. [2005.11.01]
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. [2005.10]
Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. [2005.10]
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). [2005.09]
Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. [2005.09]
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. [2005.08]
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. [2005.08]
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). [2005.06.01]
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. [2005.06]
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. [2005.02.01]
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. [2005.02]
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. [2005.01.15]
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. [2004.11]
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. [2004.11]
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. [2004.10]
Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. [2004.09]
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. [2004.09]
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. [2004.08]
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. [2004.07.15]
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. [2004.07]
Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. [2004.05]
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme. [2004.05]
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. [2004.05]
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. [2004.05]
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. [2004.04]
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. [2004.03]
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy. [2004.02]
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study. [2004.01]
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. [2003.12.01]
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. [2003.12]
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. [2003.10]
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. [2003.08]
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). [2003.07.15]
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. [2003.06.01]
The effect of erythromycin on the pharmacokinetics of rosuvastatin. [2003.05]
Effect of itraconazole on the pharmacokinetics of rosuvastatin. [2003.04]
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. [2003.02]
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. [2003.01.01]
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. [2003.01]
Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. [2003]
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. [2003]
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. [2002.12]
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. [2002.12]
No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. [2002.12]
The effect of fluconazole on the pharmacokinetics of rosuvastatin. [2002.11]
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. [2002.11]
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. [2002.02.01]
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. [2002]
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. [2001.12]
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. [2001.09.01]
Well-designed clinical trials possibly related to Crestor (Rosuvastatin)
Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies. [2008.06.01]
Randomized clinical outcome trials of statins in heart failure. [2008.04]
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. [2008]
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. [2007.12.01]
Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. [2007.12]
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. [2007.06]
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). [2007.06]
Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. [2007.03]
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. [2007.02]
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. [2007.02]
|
